Trial Profile

A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ridaforolimus (Primary)
Indications Lymphoma; Nervous system neoplasms; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

15 Jun 2019 This trial has been completed in France as per European Clinical Trials Database record.
07 Jun 2018 Status changed from active, no longer recruiting to discontinued.
01 Feb 2018 Planned End Date changed from 16 Jan 2018 to 9 Jul 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com